BMEA vs. ANNX, PEPG, TBPH, FULC, CRBP, HRTX, SLRN, MREO, LXRX, and ESPR
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Annexon (ANNX), PepGen (PEPG), Theravance Biopharma (TBPH), Fulcrum Therapeutics (FULC), Corbus Pharmaceuticals (CRBP), Heron Therapeutics (HRTX), Acelyrin (SLRN), Mereo BioPharma Group (MREO), Lexicon Pharmaceuticals (LXRX), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Annexon presently has a consensus target price of $14.14, suggesting a potential upside of 226.62%. Biomea Fusion has a consensus target price of $53.25, suggesting a potential upside of 335.05%. Given Annexon's higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Annexon.
96.7% of Biomea Fusion shares are owned by institutional investors. 19.1% of Annexon shares are owned by insiders. Comparatively, 26.3% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Annexon has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.33, suggesting that its share price is 133% less volatile than the S&P 500.
Annexon received 12 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 73.33% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Biomea Fusion's return on equity of -56.52% beat Annexon's return on equity.
In the previous week, Annexon had 29 more articles in the media than Biomea Fusion. MarketBeat recorded 29 mentions for Annexon and 0 mentions for Biomea Fusion. Annexon's average media sentiment score of 1.00 beat Biomea Fusion's score of 0.39 indicating that Biomea Fusion is being referred to more favorably in the news media.
Summary
Annexon beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
